REINVENT 2.0: An AI Tool for De Novo Drug Design.

Journal: Journal of chemical information and modeling
Published Date:

Abstract

In the past few years, we have witnessed a renaissance of the field of molecular de novo drug design. The advancements in deep learning and artificial intelligence (AI) have triggered an avalanche of ideas on how to translate such techniques to a variety of domains including the field of drug design. A range of architectures have been devised to find the optimal way of generating chemical compounds by using either graph- or string (SMILES)-based representations. With this application note, we aim to offer the community a production-ready tool for de novo design, called REINVENT. It can be effectively applied on drug discovery projects that are striving to resolve either exploration or exploitation problems while navigating the chemical space. It can facilitate the idea generation process by bringing to the researcher's attention the most promising compounds. REINVENT's code is publicly available at https://github.com/MolecularAI/Reinvent.

Authors

  • Thomas Blaschke
    Hit Discovery, Discovery Sciences, Innovative Medicines and Early Development Biotech Unit, AstraZeneca R&D Gothenburg, 431 83, Mölndal, Sweden.
  • Josep Arús-Pous
    Hit Discovery, Discovery Sciences, R&D, AstraZeneca, Pepparedsleden 1, Gothenburg 43183, Sweden.
  • Hongming Chen
    Hit Discovery, Discovery Sciences, Innovative Medicines and Early Development Biotech Unit, AstraZeneca R&D Gothenburg, 431 83, Mölndal, Sweden.
  • Christian Margreitter
    Hit Discovery, Discovery Sciences, R&D, AstraZeneca, Pepparedsleden 1, Gothenburg 43183, Sweden.
  • Christian Tyrchan
    Medicinal Chemistry, Early RIA, Biopharmaceuticals R&D, AstraZeneca, Pepparedsleden 1, Gothenburg 43183, Sweden.
  • Ola Engkvist
    Hit Discovery, Discovery Sciences, Innovative Medicines and Early Development Biotech Unit, AstraZeneca R&D Gothenburg, 431 83, Mölndal, Sweden.
  • Kostas Papadopoulos
    Hit Discovery, Discovery Sciences, R&D, AstraZeneca, Pepparedsleden 1, Gothenburg 43183, Sweden.
  • Atanas Patronov
    Hit Discovery, Discovery Sciences, R&D, AstraZeneca, Pepparedsleden 1, Gothenburg 43183, Sweden.